Navigation Links
Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast

Fourth Quarter 2007 Financial Results

VANCOUVER, Jan. 22 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, will host a conference call discussing its financial results for the fourth quarter and year ended December 31, 2007.

Thursday, February 14, 2008 at 11:00 AM ET

(8:00 AM Pacific, 9:00 AM Mountain, 10:00 AM Central)

Dial information is as follows:

North America (toll-free): (866) 510-0711

International: (617) 597-5379

Enter passcode: 91184096

A live webcast will be available to all interested parties through Angiotech's website at in the Investor Relations section.

A press release announcing Angiotech's financial results will be issued prior to the conference call at approximately 8:00 AM ET (5:00 AM Pacific, 6:00 AM Mountain, 7:00 AM Central).

A replay archive of the conference call will be available until February 21, 2008.

Replay information is as follows:

North America: (888) 286-8010

International: (617) 801-6888

Enter passcode: 85112963

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX, ANP) please visit our website at

CONTACT: Jodi Regts, Senior Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,; Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056,

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech and Symphony Medical Announce Licensing Agreement
2. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
3. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
4. Angiotech to participate in RBC 2007 Healthcare Conference
5. Angiotech to participate in Bank of America 2007 Credit Conference
6. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
7. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Angiotech to participate in UBS Global Life Sciences Conference
10. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
11. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):